IJ
Innovative Health Initiative Joint Undertaking (IHI JU)

Boosting innovation through better integration of fragmented health R&I efforts

Funds public-private research that connects fragmented health R&I efforts into shared tools, data, platforms and manufacturing processes.

Single-stage RIA proposals are capped at 50 pages for Part B. Beyond the core form, several annexes are compulsory: a detailed budget-and-participants table, a declaration of in-kind contribution commitment, and a statement on clinical studies -- even a proposal with no clinical studies at all must upload a declaration saying so. A separate annex for in-kind contributions to additional activities …

Applicants define their own project within this objective, but outcomes must integrate fragmented health R&I efforts into tools, data, platforms, technologies or processes for prediction, prevention, diagnosis, treatment or disease management. It explicitly covers innovative manufacturing (3D printing, on-demand small-scale GMP synthesis, portable production) and greener healthcare delivery.

CycleiHow often this grant runs - e.g. annually, on a rolling basis, or a one-off call.No fixed schedule
Next deadlineiThe next date applications are due. Rolling means you can apply any time.-
Decision timeiTypical time from the deadline to the funder's decision.-
Project durationiHow long the funded work is expected to run.-
Award typeiThe form of funding - grant, equity, loan, tax credit, etc.Grant
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.-
Funding pooliThe total budget available across all awards in this round.€110M

Sign up free to see the funding breakdown

Sign up free to see the industries in scope

Sign up free to see the full eligibility

Sign up free to see how to apply

Sign up free to see what you submit

Sign up free to see the timeline

Sign up free to see where teams trip up

Guides for this application

All guides →
IJ
Open

An AI Foundation Toxicology Model and Framework to Support Waiving a Second Species in Drug Safety Studies

🇨🇦IHI JU · European Union

Funds development of an AI toxicology model that lets drug developers waive costly second-species animal safety testing.

MedtechAI
€9MOct'26
IJ
Open

Decode the Immunoscience of age-related diseases

🇪🇺IHI JU · European Union

Funds a research consortium that studies why immune-mediated diseases behave differently when they first strike older adults and hunts for biomarkers to predict them.

BiotechMedtech
€9.2MOct'26
IJ
Open

IHI European HealthCare Incubator Network

🇨🇦IHI JU · European Union

Funds a pan-European industry-and-academia incubator network that re-grants up to EUR 2,000,000 each to early-stage healthcare startups.

MedtechBiotech
€35MOct'26
IJ
Closed

AI-Powered Signal Detection in Pharmacovigilance

🇪🇺IHI JU · European Union

Funds one project to build AI algorithms, data-source guidance and practical tools for faster, more accurate detection of drug safety signals.

MedtechAI
€8.9M
IJ
Closed

Boosting innovation for a better understanding of the determinants of health

🇪🇺IHI JU · European Union

Funds public-private research on the determinants of health, from prevention and early diagnosis to new vaccine strategies and disease-outbreak preparedness.

Medtech
€8M – €30M
IJ
Closed

Boosting innovation for better assessment of the added value of innovative integrated healthcare solutions

🇪🇺IHI JU · European Union

Funds public-private research on new health technology assessment methods that value combined, integrated healthcare innovations fairly.

Medtech
€5M – €9.8M
European Commission logo
Scheduled

Horizon Health: Bio-printing for Regenerative Medicine

🇪🇺European Commission · European Union

Funds €7–10M projects that advance living-cell bio-printing from laboratory proof toward regenerative medicine.

BiotechMedtech
€7M – €10MSep'27
European Commission logo
Scheduled

Clinical trials for advancing innovative interventions for neurodegenerative diseases

🇪🇺European Commission · European Union

Funds early clinical trials of safer, more effective interventions for non-rare neurodegenerative diseases.

MedtechBiotech
€10MApr'27
European Commission logo
Scheduled

Horizon Health: Antibody Therapies for Emerging Viruses

🇪🇺European Commission · European Union

Funds €9–10M projects that turn monoclonal antibodies into prevention and treatment options for one emerging virus.

BiotechMedtech
€9M – €10MApr'27
European Commission logo
Scheduled

Horizon Health: Virtual Human Twins for Clinical Decision Support

🇪🇺European Commission · European Union

Funds €10–12M projects that make Virtual Human Twins useful for prevention, diagnosis and safer clinical decisions.

AIMedtech
€10M – €12MSep'27
European Commission logo
Scheduled

Horizon Health: Flavivirus Antibody Therapies

🇪🇺European Commission · European Union

Funds €9–10M projects that turn monoclonal antibodies into prevention and treatment options for one Flavivirus.

BiotechMedtech
€9M – €10MApr'27
Department for Science, Innovation and Technology logo
Open

Life Sciences Transformational R&D Investment Fund (TRIF) Pilot

🇬🇧DSIT · United Kingdom

Capital grants for large-scale UK life sciences R&D investments.

BiotechMedtech+1
£5M – £25MApr'28